{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T22:41:42Z","timestamp":1788907302114,"version":"build-2803163510"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:00:00Z","timestamp":1760832000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["422744262 \\u2013 TRR 289"],"award-info":[{"award-number":["422744262 \\u2013 TRR 289"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["A12"],"award-info":[{"award-number":["A12"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.clim.2025.110611","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T22:39:22Z","timestamp":1760827162000},"page":"110611","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Hypothalamic pituitary adrenal axis hormone changes during IL-17A inhibition with secukinumab in patients with psoriasis"],"prefix":"10.1016","volume":"282","author":[{"given":"F.","family":"Krefting","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"H\u00f6lsken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Sondermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schedlowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2025.110611_bb0005","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.clim.2025.110611_bb0010","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2025.110611_bb0015","article-title":"Common fundamentals of psoriasis and depression","volume":"101, adv00609","author":"Holsken","year":"2021","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.clim.2025.110611_bb0020","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2025.110611_bb0025","first-page":"467","article-title":"Psoriasis as a systemic disease","volume":"121","author":"Mrowietz","year":"2024","journal-title":"Dtsch. Arztebl. Int."},{"key":"10.1016\/j.clim.2025.110611_bb0030","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2025.110611_bb0035","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2025.110611_bb0040","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.clim.2025.110611_bb0045","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1038\/jid.2009.112","article-title":"The risk of stroke in patients with psoriasis","volume":"129","author":"Gelfand","year":"2009","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.clim.2025.110611_bb0050","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1038\/jid.2015.87","article-title":"Psoriasis and the risk of major cardiovascular events: cohort study using the clinical practice research datalink","volume":"135","author":"Parisi","year":"2015","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.clim.2025.110611_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002739","article-title":"Evidence of a causal relationship between body mass index and psoriasis: a mendelian randomization study","volume":"16","author":"Budu-Aggrey","year":"2019","journal-title":"PLoS Med."},{"key":"10.1016\/j.clim.2025.110611_bb0060","first-page":"29","article-title":"Baseline pathological liver function tests in patients with psoriasis support the indication for systemic therapy rather than being a reason against it: a real-world analysis","volume":"15","author":"Krefting","year":"2025","journal-title":"Psoriasis (Auckl)"},{"key":"10.1016\/j.clim.2025.110611_bb0065","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2025.110611_bb0070","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/sj.jid.5701064","article-title":"Insights into gene modulation by therapeutic TNF and IFNgamma antibodies: TNF regulates IFNgamma production by T cells and TNF-regulated genes linked to psoriasis transcriptome","volume":"128","author":"Haider","year":"2008","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.clim.2025.110611_bb0075","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2016.08.008","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.clim.2025.110611_bb0080","first-page":"675","article-title":"Cytokines of the IL-17 family in psoriasis","volume":"18","author":"Lauffer","year":"2020","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"10.1016\/j.clim.2025.110611_bb0085","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2025.110611_bb0090","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature14175","article-title":"Clinical improvement in psoriasis with specific targeting of interleukin-23","volume":"521","author":"Kopp","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.clim.2025.110611_bb0095","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.det.2014.09.002","article-title":"The immunopathogenesis of psoriasis","volume":"33","author":"Kim","year":"2015","journal-title":"Dermatol. Clin."},{"key":"10.1016\/j.clim.2025.110611_bb0100","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 cells","volume":"27","author":"Korn","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.clim.2025.110611_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014108","article-title":"Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis","volume":"5","author":"Res","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.clim.2025.110611_bb0110","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2133.2008.08902.x","article-title":"Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin","volume":"160","author":"Johansen","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.clim.2025.110611_bb0115","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1208\/s12248-017-0094-4","article-title":"Ultra-sensitive measurement of IL-17A and IL-17F in psoriasis patient serum and skin","volume":"19","author":"Soderstrom","year":"2017","journal-title":"AAPS J."},{"key":"10.1016\/j.clim.2025.110611_bb0120","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1111\/jdv.16180","article-title":"Real-world evidence of secukinumab in psoriasis treatment - a meta-analysis of 43 studies","volume":"34","author":"Augustin","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.clim.2025.110611_bb0125","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1080\/09546634.2020.1746734","article-title":"Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life","volume":"31","author":"Gerdes","year":"2020","journal-title":"J. Dermatolog. Treat."},{"key":"10.1016\/j.clim.2025.110611_bb0130","article-title":"Secukinumab exhibits sustained and stable response in patients with moderate-to-severe psoriasis: results from the SUPREME study","volume":"101, adv00576","author":"Costanzo","year":"2021","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.clim.2025.110611_bb0140","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/jcph.876","article-title":"Population pharmacokinetic modeling of Secukinumab in patients with moderate to severe psoriasis","volume":"57","author":"Bruin","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.clim.2025.110611_bb0145","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/jdv.12751","article-title":"Efficacy, safety and usability of secukinumab administration by autoinjector\/pen in psoriasis: a randomized, controlled trial (JUNCTURE)","volume":"29","author":"Paul","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.clim.2025.110611_bb0150","author":"U.S. Food and Drug Administration"},{"key":"10.1016\/j.clim.2025.110611_bb0155","unstructured":"U.S. Food and Drug Administration. Center for drug evaluation and research administration. Multi-disciplinary review and evaluation BIMZELX (bimekizumab-bkzx). Reference ID: 5261174 <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/761151Orig1s000MultidisciplineR.pdf>."},{"key":"10.1016\/j.clim.2025.110611_bb0160","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s13555-022-00880-1","article-title":"Efficacy, safety and pharmacokinetics of IL-17 monoclonal antibody injection (AK111) in patients with moderate-to-severe plaque psoriasis: a randomized, double-blinded, placebo-controlled phase Ib multidose escalation clinical study","volume":"13","author":"Jiang","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.clim.2025.110611_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.862291","article-title":"Minimal physiologically-based pharmacokinetic (mPBPK) metamodeling of target engagement in skin informs anti-IL17A drug development in psoriasis","volume":"13","author":"Ayyar","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.clim.2025.110611_bb0170","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001679","article-title":"Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials","volume":"7","author":"Sweet","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.clim.2025.110611_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2024.100287","article-title":"Guselkumab reduces disease- and mechanism-related biomarkers more than adalimumab in patients with psoriasis: a VOYAGE 1 substudy","volume":"4","author":"Blauvelt","year":"2024","journal-title":"JID Innov"},{"key":"10.1016\/j.clim.2025.110611_bb0180","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamadermatol.2024.2463","article-title":"Noninferiority of 16-week vs 8-week Guselkumab dosing in super responders for maintaining control of psoriasis: the GUIDE randomized clinical trial","volume":"160","author":"Eyerich","year":"2024","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.clim.2025.110611_bb0185","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/j.2040-4603.2016.tb00694.x","article-title":"Regulation of the hypothalamic-pituitary-adrenocortical stress response","volume":"6","author":"Herman","year":"2016","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.clim.2025.110611_bb0190","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1056\/NEJM199505183322008","article-title":"The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation","volume":"332","author":"Chrousos","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2025.110611_bb0195","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13216394","article-title":"Immunology of stress: a review article","volume":"13","author":"Alotiby","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.clim.2025.110611_bb0200","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/bs.vh.2018.01.023","article-title":"DHEA modulates immune function: a review of evidence","volume":"108","author":"Prall","year":"2018","journal-title":"Vitam. Horm."},{"key":"10.1016\/j.clim.2025.110611_bb0205","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/j.1365-2133.2010.09984.x","article-title":"How stress gets under the skin: cortisol and stress reactivity in psoriasis","volume":"163","author":"Evers","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.clim.2025.110611_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpsychores.2023.111350","article-title":"Stress and psoriasis: exploring the link through the prism of hypothalamo-pituitary-adrenal axis and inflammation","volume":"170","author":"Rajasekharan","year":"2023","journal-title":"J. Psychosom. Res."},{"key":"10.1016\/j.clim.2025.110611_bb0215","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/921819","article-title":"Association of psoriasis severity with serum prolactin, thyroid hormones, and cortisol before and after treatment","volume":"2013","author":"Robati","year":"2013","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.clim.2025.110611_bb0220","first-page":"9","article-title":"Shaping treatment expectation to optimize efficacy of interleukin 17A antagonist Secukinumab in psoriasis patients","volume":"15","author":"Holsken","year":"2025","journal-title":"Psoriasis (Auckl)"},{"key":"10.1016\/j.clim.2025.110611_bb0225","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-047099","article-title":"Expectation-induced enhancement of pain, itch and quality of life in psoriasis patients: study protocol of a randomised controlled trial","volume":"11","author":"Holsken","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.clim.2025.110611_bb0230","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2307\/2136404","article-title":"A global measure of perceived stress","volume":"24","author":"Cohen","year":"1983","journal-title":"J. Health Soc. Behav."},{"key":"10.1016\/j.clim.2025.110611_bb0235","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1016\/j.lfs.2003.05.007","article-title":"Reproducibility of the circadian rhythms of serum cortisol and melatonin in healthy subjects: a study of three different 24-h cycles over six weeks","volume":"73","author":"Selmaoui","year":"2003","journal-title":"Life Sci."},{"key":"10.1016\/j.clim.2025.110611_bb0240","doi-asserted-by":"crossref","DOI":"10.1111\/srt.13405","article-title":"The effect of secukinumab treatment for psoriasis on serum cytokines and correlation with disease severity","volume":"29","author":"Wu","year":"2023","journal-title":"Skin Res. Technol."},{"key":"10.1016\/j.clim.2025.110611_bb0275","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/2091254a0","article-title":"Cortisol and the immune response","volume":"209","author":"Sorem","year":"1966","journal-title":"Nature"},{"key":"10.1016\/j.clim.2025.110611_bb0280","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1007\/s13555-024-01255-4","article-title":"Secukinumab in the treatment of psoriasis: a narrative review on early treatment and real-world evidence","volume":"14","author":"Malagoli","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.clim.2025.110611_bb0285","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2025.110611_bb0290","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41574-022-00683-6","article-title":"Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions","volume":"18","author":"Li","year":"2022","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.clim.2025.110611_bb0295","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1210\/er.2018-00097","article-title":"Glucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy","volume":"39","author":"Hardy","year":"2018","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.clim.2025.110611_bb0300","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2213-8587(16)00086-3","article-title":"Complications of Cushing's syndrome: state of the art","volume":"4","author":"Pivonello","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.clim.2025.110611_bb0305","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.bbi.2019.12.012","article-title":"Interleukin-17 acts in the hypothalamus reducing food intake","volume":"87","author":"Nogueira","year":"2020","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.clim.2025.110611_bb0310","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/s42255-023-00846-3","article-title":"Interleukin-17 as a key player in neuroimmunometabolism","volume":"5","author":"Douglas","year":"2023","journal-title":"Nat. Metab."},{"key":"10.1016\/j.clim.2025.110611_bb0315","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.addr.2019.02.004","article-title":"Chronopharmacology of glucocorticoids","volume":"151-152","author":"Scherholz","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.clim.2025.110611_bb0320","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1152\/physrev.00021.2023","article-title":"Glucocorticoids, their uses, sexual dimorphisms, and diseases: new concepts, mechanisms, and discoveries","volume":"104","author":"Martinez","year":"2024","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.clim.2025.110611_bb0325","doi-asserted-by":"crossref","DOI":"10.3389\/phrs.2021.1603990","article-title":"A review of inflammatory bowel disease: a model of microbial, immune and neuropsychological integration","volume":"42","author":"Tavakoli","year":"2021","journal-title":"Public Health Rev."},{"key":"10.1016\/j.clim.2025.110611_bb0330","doi-asserted-by":"crossref","first-page":"746","DOI":"10.5114\/ada.2019.83975","article-title":"Adrenocorticotropin\/cortisol ratio - a marker of psoriasis severity","volume":"37","author":"Pietrzak","year":"2020","journal-title":"Postepy Dermatol. Alergol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152166162500186X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152166162500186X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:44:09Z","timestamp":1778816649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152166162500186X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":59,"alternative-id":["S152166162500186X"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2025.110611","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypothalamic pituitary adrenal axis hormone changes during IL-17A inhibition with secukinumab in patients with psoriasis","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2025.110611","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110611"}}